Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Long-Term Debt, Maturity, Remainder of Fiscal Year

1.9 / 5 stars · 34/88 Roast Me

AKEBIA THERAPEUTICS, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year

AKEBIA THERAPEUTICS, INC. (AKBA) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Notes › Commitment and Contingencies

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-08-05

  • 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
  • 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
  • 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
  • 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
Period endLong-Term Debt, Maturity, Remainder of Fiscal Year
2026-06-30$0.00
10-Q · filed 2026-08-05
2026-03-31$0.00
10-Q · filed 2026-05-07
2025-09-30$0.00
10-Q · filed 2025-11-10
2025-06-30$0.00
10-Q · filed 2025-08-07
2025-03-31$0.00
10-Q · filed 2025-05-08
2024-09-30$0.00
10-Q · filed 2024-11-07
2024-06-30$0.00
10-Q · filed 2024-08-08
2024-03-31$0.00
10-Q · filed 2024-05-09
2022-09-30$0.00
10-Q · filed 2022-11-03
2022-06-30$33.00M
10-Q · filed 2022-08-04
2020-09-30$0.00
10-Q · filed 2020-11-05
2020-06-30$0.00
10-Q · filed 2020-08-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33